The MOHW’s new budget focuses on new drugs·COVID-19 trial

Net increase in government regenerative medicine technology development, digital pathology cancer AI business

While the budget plan of the MOHW for 2021 was released, it was found that the new budget focused on the treatment field, such as the national new drug development project and non-clinical support for COVID-19 treatment and vaccine.

 

The new budget for the national new drug development project was ￦150.5 billion, and the new budget for non-clinical support for COVID-19 treatment and vaccine was ￦7.4 billion.

 

In particular, compared to the previous year, the budget for clinical support for COVID-19 treatments and vaccines increased by ￦17.7 billion to ￦62.7 billion, and vaccines increased by ￦19.7 billion to ￦68.7 billion.

 

Looking at the 2021 budget for the Ministry of Health and Welfare, Health Industry Policy Bureau of the Ministry of Health and Welfare on the 8th, 27.0% of the total ￦934.3 billion requested by the MOHW is adjusted to ￦79.37 million.

 

Among them, the new net increase budget next year was ▲general government regenerative medical technology development project (R&D) ▲national drug development project ▲disease-centered mediation research project (R&D) ▲public interest medical technology research (R&D) ▲digital pathology-based Cancer-specialized AI analysis solution development project (R&D) ▲ Big data construction specialized for critically ill patients and AI-based CDSS development (R&D) ▲ Multilateral life research resource advancement project ▲ COVID-19 treatment/vaccine non-clinical support.

 

What stands out are the national new drug development project and non-clinical support for COVID-19 treatments and vaccines.

 

The national new drug development project, with a net increase of ￦15.1 billion, aims to become a competitive blockbuster new drug in the global market, and supports the entire cycle of new drug development from discovery of candidate substances to phase II clinical trials.

 

It is conducted by the Ministry of Welfare, the Ministry of Science and ICT, and the Ministry of Industry, and the next year's budget is only reflected for six months, considering the preparation period for the first year.

 

The main contents are the 'new drug base expansion research' budget of ￦3.93 billion, which aims to continue supplying excellent initial pipelines, and the'new drug clinical development' budget of ￦3.7 billion, to vitalize the entry of basic research results into the clinical stage.

 

Non-clinical support for COVID-19 treatment and vaccine was allocated ￦7.4 billion.

 

￦6.4 billion is for non-clinical support, and ￦1 billion is for medical product evaluation support using advanced animals.

 

￦7.17 billion was allocated for the development of a digital pathology-based AI analysis solution specializing in cancer.

 

It costs ￦2.62 billion for the expansion of the pathology data digital curation base, ￦1.68 billion for the development of a digital pathology data platform for AI development, and ￦2.62 billion for the development of intelligent pathology AI SW specializing in cancer.

 

In addition, ￦6.41 billion was allocated for the regenerative medical technology development project of all ministries.

 

It consisted of ￦1.98 billion for regenerative medicine source technology development, ￦2.64 billion for regenerative medicine-linked technology development, ￦702 million for regenerative medical treatment technology development, and ￦1,158 million for operating expenses.

 

The government’s regenerative medicine technology development project secures core and source technologies in the field of regenerative medicine, and supports the development of linked technologies, treatments, and treatment technologies and early clinical application.

 

The disease-centered mediation research project was allocated ￦3.63 billion, the public medical technology research project was ￦4,17 million, and the critically ill-specialized big data construction project was allocated ￦7.06 billion.

 

The public medical technology research project aims to verify the concept and secure clinical basis by supporting the development of practical technology for solving public medical demand such as low birthrate, rare diseases, and patient safety.

 

On the other hand, the MOHW has organized the budget for clinical support for COVID-19 treatment and vaccines, which is also higher than the previous year.

 

In the case of clinical support for treatment, ￦62.7 billion was allocated, an increase of ￦17.7 billion (39.3%) from ￦45 billion, and vaccine clinical support was allocated ￦68.7 billion, an increase of ￦19.7 billion (40.2%) from ￦49 billion.